Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649218 | 0.88 | HTR2A (0.46) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL4649259 | 0.83 | HTR2A (0.48) | CHRNB2CHRNA4HTR1ADRD2HTR2A | |
| SCHEMBL4649409 | 0.80 | CHRNB2 (0.56) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL4649244 | 0.79 | HTR6 (0.53) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL4649915 | 0.79 | HTR6 (0.52) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL4650585 | 0.79 | HTR6 (0.52) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL4649408 | 0.78 | HTR6 (0.48) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL4649227 | 0.78 | HTR1A (0.49) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNA4 | |
| SCHEMBL4649900 | 0.78 | HTR1A (0.49) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNA4 | |
| SCHEMBL4650645 | 0.78 | HTR6 (0.54) | HTR1ADRD2HTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730112-B1 | 3-((HETERO)ARYLSULFONYL)-8'[ (AMINOALKYL)OXY]QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | claimed |
| US-20070191345-A1 | 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | claimed |
| EP-1730112-A1 | 3-((HETERO)ARYLSULFONYL)-8'[ (AMINOALKYL)OXY]QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | claimed |
| WO-2005095346-A1 | 3-((HETERO)ARYLSULFONYL)-8-` (AMINOALKYL)OXY!QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | claimed |
| EP-1730112-B1 | 3-((HETERO)ARYLSULFONYL)-8'[ (AMINOALKYL)OXY]QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1904063-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF DYSKINESIAS CAUSED BY A CHEMICAL TREATMENT | Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S) SAS (FR) | 2008-04-02 | — | — | EP | disclosed |
| US-20070191345-A1 | 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070191345-A1 | 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070191345-A1 | 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| WO-2007006942-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF DYSKINESIAS CAUSED BY A CHEMICAL TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2007-01-18 | — | — | WO | disclosed |
| EP-1730112-A1 | 3-((HETERO)ARYLSULFONYL)-8'[ (AMINOALKYL)OXY]QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095346-A1 | 3-((HETERO)ARYLSULFONYL)-8-` (AMINOALKYL)OXY!QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191345-A1 | 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders | HTR6, HTR3B, HTR2C | CHRNB4 233/4885CHRNA3 82/4885CHRNB2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.